Efficacy and Cost Effectiveness Analysis of Five Different Therapeutic Schemes for Chronic Hepatitis B

Objective To observe the clinical efficacy and the economic effectiveness of different therapeutic schemes for Chronic hepatitis UB.Methods Patients with Chronic Hepatitis B were treated by using different drugs:Interferon α1b(group A),Lamivudine(group B),Interferon α1b combination with Lamivudine(group C),Interferon α1b combination with thymotentin(group D),Interferon α1b combination with thymosin alphal(group E).Evaluation was carried out with pharmacoeconomic cost-effectiveness.Results At the end of therapy,the clearance rate of serum HbeAg was lowest in group B(10 94%),the other groups were more than 50%.The clearance rate of serum HBV-DNA was higher in group B and C than in the other groups,it was 85 94%,87 93% respectively.Normalizing ALT values was higher in group C,group D and group E than in group A and group B.The costs of several therapeutic schemes were RMB 8156 7(group A),6935(group B),15091 7(group C),26033 4(group D) and 89978 4(group E) yuans,respectively.Conclusions According to the evaluation with pharmacoeconomic cost-effectiveness analysis,the therapeutic scheme of Interferon α1b,Lamivudine and Interferon α1b combination with Lamivudine is best one for treating chronic hepatitsi B,in this groups,Interferon α1b combination with Lamivudine was better than the other two groups.